Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA])…
Also tagged Adults, Aifa, Basilea Pharmaceutica, Eczema, Farmaco, Hand Eczema, Italy, Marketing, Oral Treatment
Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that Toctino® (alitretinoin) was recommended for regulatory approval under the Repeat-use Procedure in 13 additional European Union (EU) Member States as well as in Norway and Iceland. Toctino® is a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids…
Also tagged Adults, Basilea, Bsln, Eczema, European Countries, European Union, Hand Eczema, Iceland, Member States, Norway, Oral Treatment, Regulatory Approval, Swiss
Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has obtained regulatory approval from Health Canada. “We are delighted that Health Canada has approved the use of Toctino for patients with severe chronic hand eczema [...]
Also tagged Adults, Basilea Pharmaceutica, Eczema, Hand Eczema, Health Canada, Marketing, Oral Treatment, Regulatory Approval, Topical Steroids
Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the National Institute for Health and Clinical Excellence (NICE) issued its final guidance recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids.
Also tagged Adults, Basilea Pharmaceutica, Bsln, Clinical Excellence, Eczema, Guidance, Hand Eczema, National Institute For Health, Swiss, Treatment Option
Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the National Institute for Health and Clinical Excellence (NICE) issued the Final Appraisal Determination (FAD) recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids.
Also tagged Adults, Basilea Pharmaceutica, Bsln, Clinical Excellence, Eczema, Fad, Hand Eczema, National Institute For Health, Swiss, Treatment Option
Basilea Pharmaceutica Ltd. (SWISS: BSLN) (PINKSHEETS: BPMUF) announces that the Appraisal Committee of the National Institute for Health and Clinical Excellence (NICE) has developed preliminary positive recommendations with some limitations on the use of Toctino® (alitretinoin) within its licensed indication, as treatment for adults with severe chronic hand eczema that has not responded to potent [...]
Also tagged Adults, Appraisal Committee, Basilea Pharmaceutica, Bsln, Clinical Excellence, Eczema, Hand Eczema, National Health, National Institute For Health, Pinksheets, Swiss
Chronic plaque psoriasis is the most common type of psoriasis and is characterised by redness, thickness and scaling. First line management of chronic plaque psoriasis is with topical treatments, including vitamin D analogues, topical corticosteroids, tar-based preparations, dithranol, salicylic acid and topical retinoids.
Also tagged Analogues, Chronic Plaque Psoriasis, Line Management, Plaque Psoriasis, Psoriasis, Psoriasis Treatments, Salicylic Acid, Tar, Topical Retinoids, Topical Treatments, Vitamin D
